# Nuclein

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nuclein

- Industry: Biotechnology
- Headquarters: Austin, US
- Website: www.nuclein.com
- Total disclosed funding: $14M
- Latest round: Series B (Mar 25, 2021)
- Investors on record: 1

## About

Based in Texas, US, and founded in 2017, Nuclein, LLC is a medical device company that develops hand-held polymerase chain reaction (PCR) test designed to be a disposable, all-in-one, and self-test for infectious disease diagnosis.  The company was co-founded by Alan Blake and Richard Crockett and is backed by notable individual investors and the recent Series B funding round led by Trinity Private Equity Group. 

Nuclein hand-held PCR Test uses standard, real-time PCR and does not require technical expertise. The device is battery-powered and produces quick results in under one hour without the need to mail in a sample.  

Nuclein plans to apply to the U. S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) to commercialize its COVID-19 testing device, and hire additional molecular biologists, engineers, and manufacturing staff to support its growth.

## Funding rounds

- Series B, Mar 25, 2021, $14M — Trinity Private Equity Group

## Investors

- Trinity Private Equity Group (https://capitalatlas.ai/funds/trinity-private-equity-group) — Series B